Rebecca Bruning-Barry

Rebecca Barry, PhD, is the Director of the Regulatory Strategy and Product Development Program at RTI where she manages a multidisciplinary team that specializes in translational research and medical product development. She supports a portfolio of research programs funded by the National Institutes of Health (NIH), small biotechnology companies, and non-profit organizations, and her work focuses on public-sector and private-sector collaborations to develop drugs to combat infectious diseases such as HIV and tuberculosis (TB).

Dr. Barry is currently the Project Director overseeing the collaboration with the Global Alliance for TB Drug Development and provides nonclinical strategy and consulting for a number of academic investigators and small biotechnology companies. She has 8 years of prior drug development experience from working at a contract research organization and as a consultant in drug discovery and preclinical drug development programs. Dr. Barry has conducted pharmacology, toxicology, and efficacy studies in multiple species and animal models of disease for a variety of therapeutic indications. She is experienced at study monitoring and directing nonclinical operations and timeline management; performing gap analyses; and authoring, reviewing, and providing quality control for sections of Investigations New Drug (IND) applications and Investigators Brochures submitted to the FDA for small molecules, biologics, vaccines, and gene therapy projects.

Prior to joining RTI in 2017, Dr. Barry worked at a preclinical contract research organization, Covance (Labcorp), as a Pharmacology and Toxicology Study Director. She has authored a book chapter and several publications on nonclinical programs and currently holds a professional membership in the American College of Toxicology.